公司資料
Nuvalent 股價、新聞與催化劑
- 股票代碼:
- NUVL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
123.96 USD (+0.02%)
收盤價
最後更新: 2026年7月14日
7.22B USD
市值
股價為何變動
Current closing-price context is not available for NUVL.
公司概覽
業務概覽
Nuvalent is a precision-oncology company developing next-generation kinase inhibitors for genetically defined cancers.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Nuvalent sits in targeted oncology biotechnology.
商業模式特徵
The company depends on differentiated clinical data, molecule design, and the possibility of building best-in-class oncology assets.
生技產業定位
Nuvalent is a high-quality targeted-therapy name whose stock reacts quickly to efficacy and safety differentiation.
未來催化劑
- Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium. The company still needs each update to reinforce its differentiation.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。